PE99499A1 - PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES - Google Patents

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES

Info

Publication number
PE99499A1
PE99499A1 PE1998000630A PE00063098A PE99499A1 PE 99499 A1 PE99499 A1 PE 99499A1 PE 1998000630 A PE1998000630 A PE 1998000630A PE 00063098 A PE00063098 A PE 00063098A PE 99499 A1 PE99499 A1 PE 99499A1
Authority
PE
Peru
Prior art keywords
treatment
inahibor
diabetes
pharmaceutical composition
gautia
Prior art date
Application number
PE1998000630A
Other languages
Spanish (es)
Inventor
Stephen Alistair Smith
Robin Edwin Buckingham
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE99499A1 publication Critical patent/PE99499A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION CARACTERIZADA PORQUE COMPRENDE a)UN SENSIBILIZADOR DE INSULINA COMO 5-[4-[2-(N-METIL-N-(2-PIRIDIL)AMINO)ETOXI]-BENCIL]TIAZOLIDIN-2,4-DIONA, TROGLITAZONA, CIGLITAZONA, PIOGLITAZONA, ENGLITAZONA, b)UN SECRETAGOGO DE INSULINA, PUDIENDO SER UNA SULFONILUREA COMO GLIBENCLAMIDA, GLIPIZIDA, GLICLAZIDA, ENTRE OTROS Y c)UN AGENTE ANTIHIPERGLUCEMICO INHIBIDOR DE ALFA-GLUCOSIDASA COMO ACARBOSA, EMIGLITATO Y MIGLITOL. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DIABETES MELLITUS Y LAS CONDICIONES ASOCIADAS CON LA DIABETES MELLITUSREFERS TO A COMPOSITION CHARACTERIZED BECAUSE IT INCLUDES a) AN INSULIN SENSITIZER AS 5- [4- [2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI] -BENCIL] THIAZOLIDIN-2,4-DIONA, TROGLITAZONA, CIGLITAZONA, PIOGLITAZONA, ENGLITAZONA, b) AN INSULIN SECRETAGOGUE, MAY BE A SULFONILUREA LIKE GLIBENCLAMIDA, GLIPIZIDA, GLICLAZIDA, BETWEEN OTHERS, AND c) ANTI-HYPERGLUCEMIC AGENT, INAHIBOR ALI-GAS, AND A-GIURA, INAHIBOR, ANDI-GAUTIA, INAHIBOR, ANDI-GAUTIA THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF DIABETES MELLITUS AND THE CONDITIONS ASSOCIATED WITH DIABETES MELLITUS

PE1998000630A 1997-07-18 1998-07-16 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES PE99499A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
PE99499A1 true PE99499A1 (en) 1999-12-18

Family

ID=10816170

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000630A PE99499A1 (en) 1997-07-18 1998-07-16 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES

Country Status (27)

Country Link
EP (1) EP1001784A1 (en)
JP (1) JP2001510160A (en)
KR (1) KR20010021952A (en)
CN (1) CN1263467A (en)
AP (1) AP2000001735A0 (en)
AR (2) AR016350A1 (en)
AU (1) AU8449098A (en)
BG (1) BG104062A (en)
BR (1) BR9810292A (en)
CA (1) CA2297133A1 (en)
CO (1) CO4940489A1 (en)
DZ (1) DZ2563A1 (en)
EA (1) EA200000140A1 (en)
GB (1) GB9715298D0 (en)
HU (1) HUP0003626A3 (en)
ID (1) ID23804A (en)
IL (1) IL133907A0 (en)
MA (1) MA24608A1 (en)
NO (1) NO20000230D0 (en)
OA (1) OA11312A (en)
PE (1) PE99499A1 (en)
PL (1) PL338140A1 (en)
SK (1) SK612000A3 (en)
TR (1) TR200000133T2 (en)
UY (1) UY25101A1 (en)
WO (1) WO1999003478A1 (en)
ZA (1) ZA986364B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ATE372782T1 (en) 1999-06-21 2007-09-15 Lilly Co Eli SYNERGITIC USE OF THIAZOLIDINEDIONES AND GLUCAGONE-LIKE PEPTIDE-1 AND THEIR AGONISTS FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES
JP2003520226A (en) * 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト Combination comprising a dipeptidyl peptidase-IV inhibitor and an antidiabetic agent
WO2001062295A1 (en) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Drugs containing combined active ingredients
JP4917712B2 (en) * 2000-02-24 2012-04-18 武田薬品工業株式会社 Concomitant medication
EP1738751B1 (en) 2001-01-12 2011-05-11 Sun Pharma Advanced Research Company Ltd Spaced drug delivery system
FR2832930A1 (en) * 2001-12-03 2003-06-06 Lipha PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES
CA2540225C (en) 2003-10-31 2012-03-06 Takeda Pharmaceutical Company Limited Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
CN101103993B (en) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 Hypoglycemic medicine composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2101866T3 (en) * 1991-08-26 1997-07-16 Upjohn Co LIQUID FOOD PRODUCT CONTAINING 3-GUANIDINOPROPIONIC ACID.
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
EA200000140A1 (en) 2000-06-26
CN1263467A (en) 2000-08-16
TR200000133T2 (en) 2000-09-21
SK612000A3 (en) 2000-07-11
IL133907A0 (en) 2001-04-30
JP2001510160A (en) 2001-07-31
AP2000001735A0 (en) 2000-01-16
DZ2563A1 (en) 2003-02-15
UY25101A1 (en) 2000-12-29
KR20010021952A (en) 2001-03-15
ZA986364B (en) 2000-01-17
CO4940489A1 (en) 2000-07-24
WO1999003478A1 (en) 1999-01-28
CA2297133A1 (en) 1999-01-28
NO20000230L (en) 2000-01-17
EP1001784A1 (en) 2000-05-24
NO20000230D0 (en) 2000-01-17
HUP0003626A2 (en) 2001-05-28
AR019724A2 (en) 2002-03-13
PL338140A1 (en) 2000-09-25
AU8449098A (en) 1999-02-10
BG104062A (en) 2000-11-30
MA24608A1 (en) 1999-04-01
BR9810292A (en) 2000-09-19
ID23804A (en) 2000-05-11
HUP0003626A3 (en) 2001-12-28
AR016350A1 (en) 2001-07-04
GB9715298D0 (en) 1997-09-24
OA11312A (en) 2003-10-24

Similar Documents

Publication Publication Date Title
PE83199A1 (en) PHARMACEUTICAL COMPOSITION OF TIAZOLIDINADIONA AND BIGUANIDE FOR THE TREATMENT OF DIABETES
PE99599A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
AR057970A2 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MELLITUS DIABETES AND CONDITIONS ASSOCIATED WITH MELLITUS DIABETES AND PROCEDURES TO PREPARE SUCH COMPOSITIONS
EA200601145A1 (en) TABLET OF SLOW-DIVISION OF INSULIN SENSITIZER AND OTHER ANTI-DIABETIC AGENTS
EA200000629A1 (en) STABILIZED TERIPARATID SOLUTIONS
ES2071339T3 (en) HYPOGLYCEMIC AND HYPOCOLESTEROLEMIC AGENTS OF OXAZOLIDINDIONA.
PE104499A1 (en) PHARMACEUTICAL COMPOSITION OF TIAZOLIDINDIONA AND INSULIN FOR THE TREATMENT OF DIABETES
EP1593379A3 (en) Uses of PPAR-gamma agonists in neutrophil-induced diseases
PE99499A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
AR046210A1 (en) SOLID PREPARATION
PE99799A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
PE89199A1 (en) PHARMACEUTICAL COMPOSITION OF TIAZOLIDINADIONA AND AN ALPHA GLUCOSIDASE INHIBITOR FOR THE TREATMENT OF DIABETES
PE108199A1 (en) PHARMACEUTICAL COMPOSITION OF TIAZOLIDINDIONA AND SULFONILUREA
EA200300005A1 (en) SALT THIAZOLIDINDION FOR THE TREATMENT OF DIABETES MELLITUS
PT1446404E (en) EDISILATES OF ROSIGLITAZONE AND ITS USE AS ANTIDIABETICS
CY1107767T1 (en) THIAZOLIDINODIONI PRODUCER AND USE OF IT AS ANTIBIOTIC
EA200300004A1 (en) HYDROIODID 5- [4- [2- (N-METHYL-N- (2-Pyridyl) AMINO) ETOXY] BENZYL] THIAZOLIDIN-2,4-DIONA AS PHARMACEUTICAL PREPARATION
CO5150180A1 (en) NEW COMPOSITION AND USE MODIFIED RELEASE
PE20030744A1 (en) TRANSDIFFERENTIATION OF PANCREATIC ACINE CELLS
ECSP982534A (en) NEW METHOD OF TREATMENT
ECSP982593A (en) NEW METHOD OF TREATMENT VI
ECSP982535A (en) NEW TREATMENT METHOD (I)
HUP0002669A2 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
TH36758A (en) Methods for the treatment of diabetes with thiazoolidine, dion and methformin.

Legal Events

Date Code Title Description
FC Refusal